Abstract Human platelets express three types of P2 receptors, which play important roles in platelet function: P2X 1 , P2Y 1 and P2Y 12 . Only patients with either quantitative or qualitative abnormalities of the platelet P2Y 12 receptor have been well-characterized so far. Deficiencies of P2Y 12 are associated with nucleotide deletions in the open-reading frame, frameshifts, and early truncation of the protein, or with a nucleotide substitution in the transduction initiation codon. Congenital dysfunctions of P2Y 12 are associated with molecular defects involving the sixth trans-membrane domain or the adjacent third extracellular loop of the receptor, which identify a region of the protein whose integrity is necessary for normal receptor function. A mutation, predicting a lysine to glutamate (Lys174Glu) substitution was associated with decreased ligand binding to the receptor, suggesting that it is responsible for disruption of the adenosine diphosphate (ADP)-binding site of the receptor. Patients with P2Y 12 defects display a mild-tomoderate bleeding diathesis, characterized by mucocutaneous bleedings and excessive post-surgical and posttraumatic blood loss. Defects of P2Y 12 should be suspected when ADP, even at high concentrations (≥10 μM), is unable to induce full, irreversible platelet aggregation. Tests that evaluate the degree of inhibition of adenylyl cyclase by ADP should be used to confirm the diagnosis.
it amplifies the platelet responses induced by other platelet agonists [1, 8, 9] , stabilizes platelet aggregates [10] [11] [12] and inhibits the antiplatelet effects of prostacyclin [13] .
The interaction of ADP with its G q -coupled, P2Y 1 receptor mediates a transient rise in cytoplasmic Ca 2+ , platelet shape change and rapidly reversible aggregation, while its interaction with the G i -coupled, P2Y 12 receptor mediates inhibition of adenylyl cyclase, phosphatidylinositol 3-kinase activation and the amplification of the platelet aggregation response [1] . About 20-30% of the plateletbinding sites for ADP are associated with P2Y 1 , while the remaining 70% are associated with P2Y 12 [1, 14] . Concomitant activation of both the G q and G i pathways by ADP is necessary to elicit normal aggregation [1, 10] .
ATP, being an antagonist of both P2Y 1 and P2Y 12 , inhibits platelet activation by ADP [15, 16] : however, through its interaction with P2X 1 , it can also activate platelets by inducing a very rapid influx of Ca 2+ from the extracellular medium, which is associated with a transient platelet shape change [17] . Platelet activation by ATP amplifies the platelet responses to other agonists, especially in flow conditions that are characterized by high shear stress [18] [19] [20] [21] [22] .
Abnormalities of the platelet P2 receptors
Abnormalities of the platelet P2X 1 receptors
Only one patient with defect of the platelet P2X 1 receptor has been described so far. She displayed a severe bleeding diathesis associated to a naturally occurring dominant negative P2X 1 mutant, lacking one leucine within a stretch of four leucine residues in its second transmembrane domain (amino acids 351-354) [23] . However, the patient also displayed a severe defect of ADP-induced platelet aggregation, which cannot be explained by the defect in P2X 1 receptor (which is activated by ATP and has no role in ADP-induced platelet aggregation) and could by itself account for the bleeding diathesis of the patient. Therefore, the relationship between genotype and phenotype in the patient described by Oury et al. is unclear.
Abnormalities of the platelet P2Y 1 receptors
Defects of the platelet P2Y 1 receptors A description of a patient with a history of bleeding following surgery and occasional weak ADP-induced platelet aggregation was published in abstract form by Oury et al. in 1999 [24] . The defect was associated with normal P2Y 1 -encoding regions in the patient's DNA, but reduced platelet levels of P2Y 1 mRNA (75% of normal), suggestive of deficient P2Y 1 gene transcription. Low P2Y 1 mRNA platelet levels were also found in a sister, son, and grandson of the index patient, but not in six other members of the family. Consistent with a deficiency of P2Y 1 , ADP did not elicit intracellular Ca 2+ mobilization in the index patient and his family members with low P2Y 1 mRNA platelet levels. However, no further details of this family have been published in a full article since this 1999 abstract.
Polymorphisms of the platelet P2Y 1 receptors
A P2Y 1 gene dimorphism, 1622AG, was associated with a significant effect on platelet ADP response, with a greater response in carriers of the G allele (frequency 0.15). The response to all tested concentrations of ADP in GG homozygotes was higher than in AA homozygotes, but greatest with 0.1 μM ADP (on average, 130% higher) [25] .
Abnormalities of the platelet P2Y 12 : reversible platelet aggregation induced by ADP concentrations ≤10 μM; full and irreversible platelet aggregation induced by concentrations of ADP ≥10 μM; impaired, but not absent inhibition of PGE 1 -induced increase in platelet cyclic AMP; impaired platelet secretion induced by several agonists. Because the platelet secretion defect is not associated with impaired production of TxA 2 or low concentrations of platelet granule contents, it is very similar to that described in patients with an ill-defined and probably heterogeneous group of congenital defect of platelet secretion, sometimes referred to with the general term "primary secretion defect" [32, 33] .
The P2Y : one mutant allele contains a deletion of two base pairs, resulting in a frameshift and early truncation of the protein. Surprisingly, the other allele did not display any mutation: the findings that the patient's platelets contained P2Y 12 transcripts derived from the mutant allele only and that his daughter, who had a heterozygous phenotype, inherited the mutant allele from her father and a normal allele from her mother, suggest that patient ML has an additional, as yet unknown mutation that silences his normal allele.
Congenital dysfunction of the platelet P2Y 12 receptors
A patient (AC) with dysfunstional P2Y 12 12 -mediated platelet responses to ADP: (a) similar to platelets with severe deficiency of P2Y 12 , platelet aggregation induced by 4 μM ADP was low and reversible, but the response to 20 μM ADP, albeit still decreased and reversible, was more pronounced and was further inhibited by a P2Y 12 antagonist, indicating residual receptor function; (b) ADP failed to lower adenylyl cyclase activity stimulated by PGE 1 . Analysis of the patient's P2Y 12 gene revealed, in one allele, a G to A transition changing the codon for Arg256 in sixth trans-membrane domain (TM6) to Gln and, in the other, a C to T transition changing the codon for Arg265 in the third extracellular loop (EL3) to Trp ( Table 2) . Neither mutation interfered with receptor surface expression but both altered receptor function, since ADP inhibited the forskolin-induced increase of cyclic AMP markedly less in cells transfected with either mutant P2Y 12 than in wild-type cells. These observations, in accordance with previous studies of the P2Y 1 receptor [38, 39], helped to identify regions in TM6 and EL3, whose structural integrity is necessary for normal receptor function. A heterozygous point mutation in the same region of the molecule, which changed codon 258 coding for proline (CCT) to threonine (ACT) (Pro258Thr), was described in a patient with mild bleeding disorder and severely impaired ADP-induced platelet aggregation [40] . Since the proline to A heterozygous mutation, predicting a lysine to glutamate (Lys174Glu) substitution in P2Y 12 , was identified in one patient with mild type 1 von Willebrand disease [41] . Platelets from this patient showed reduced and reversible aggregation in response to ADP, up to 10 μM. The reduced response was associated with an approximate 50% reduction in binding of [ 3 H]2MeS-ADP. Considering that Lys174 is situated in the second extracellular loop of P2Y 12 , adjacent to Cys175, which is linked to a Cys at position 97 residue and may be important for the expression of the ADP binding site receptor [42] [43] [44] [45] , and that a hemagglutinin-tagged Lys174Glu P2Y 12 variant showed surface expression in Chinese hamster ovary cells, it is likely that the Lys174Glu mutation is responsible for disruption of the ADP binding site of the receptor.
For reasons that are presently unclear, two patients with heterozygous dysfunctional P2Y 12 (Pro258Thr and Lys174-Glu) display a much more severe impairment of ADPinduced platelet aggregation compared to the two patients who are heterozygous for P2Y 12 deficiency [28, 29] and to the two children of patient AC, who are heterozygous for the Arg265Gln mutation [37] ( Table 2) .
Clinical features of congenital P2Y12 defects

Bleeding manifestations
Patients with defects of P2Y 12 experience mucocutaneous bleeding and excessive post-surgical or post-traumatic blood loss. The severity of their bleeding diathesis is variable. The bleeding scores of patient VR and of the two sisters, MG and IG, which was calculated using a standardized questionnaire that was developed to investigate patients with type-1 von Willebrand disease [46] were 8, 7, and 13, respectively, (normal values ≤3; unpublished data). The degree of prolongation of their bleeding times was also variable, reflecting the severity of their clinical bleeding scores: 15 and 20 min (results of two measurements in patient VR), 20 min (patient MG) and >30 min (patient IG; normal values <8 min). After extensive investigation of haemostasis parameters, which included measurement of the activity of clotting and fibrinolytic factors and the search for known polymorphisms of haemostasis proteins, we found no explanation for the discrepancy in the severity of bleeding manifestations in the two sisters, MG and IG.
The bleeding score of a patient with heterozygous P2Y 12 deficiency (GL, the son of patient MG) was normal; however, it must be noted that this young boy had not yet experienced situations that could challenge the haemostatic system at the time of our investigation. His bleeding time, despite the mild defect of P2Y 12 , was prolonged (13 min).
Diagnosis
The diagnosis of P2Y 12 defects is rather simple: they should be suspected when ADP, even at relatively high concentrations (≥10 μM), is unable to induce full, irreversible platelet aggregation, while inducing normal shape change. Tests that evaluate the degree of inhibition of adenylyl cyclase by ADP, by measuring either the platelet levels of cyclic AMP or the phosphorylation of vasodilatorstimulated phosphoprotein [47] after the exposure of platelets to PGE 1 , should be used to confirm the diagnosis.
Treatment
The intravenous infusion of the vasopressin analog desmopressin (0.3 μg/kg) shortened the prolonged bleeding time of patient VR from 20 to 8.5 min [48] . After the infusion of desmopressin, which was repeated twice at 24 h intervals, the patient underwent a surgical intervention for disk hernia repair, which was not complicated by excessive bleeding. Although the efficacy of desmopressin in reducing bleeding complications of patients with defects of primary haemostasis is anecdotal [49] , its administration is generally without serious side effects.
Polymorphisms of the P2Y 12 gene
Four polymorphisms of the P2Y 12 gene were identified, which were in total linkage disequilibrium, determining haplotypes H1 and H2, with respective allelic frequencies of 0.86 and 0.14. H2 haplotype is a gain-of-function haplotype, associated with increased ADP-induced platelet aggregation [50] . The H2 haplotype was more frequent among 184 patients with peripheral artery disease than in 330 age-matched control subjects (OR, 2.3; CI, 1.4-3.9; p= 0.002 after adjustment for diabetes, smoking, hypertension, hypercholesterolemia, and other selected platelet receptor gene polymorphisms) [51] . Several studies tested the hypothesis that common polymorphisms of the P2Y 12 gene might interfere with the antiplatelet effects of drugs inhibiting the P2Y 12 receptor, accounting for the well known individual variability in the response to these agents [52, 53] . The vast majority of these studies, with few exceptions, reported that P2Y 12 polymorphisms are not associated with altered platelet function inhibition by P2Y 12 antagonists [54] [55] [56] [57] [58] [59] [60] [61] . 
